Ligand Pharmaceuticals Incorporated (LGND)

Ligand Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1,007	174.93	72.31	22.95	45.01	19.52
Short-Term Investments	351.06	558.59	183.86	147.36	166.86	321.59
Cash & Short-Term Investments	1,358	733.52	256.17	170.31	211.87	341.11
Cash Growth	454.14%	186.35%	50.41%	-19.62%	-37.89%	-17.04%
Accounts Receivable	79.99	82.39	48.4	32.92	30.42	85.45
Other Receivables	2.91	1.45	4.07	6.4	4.61	6.19
Receivables	82.9	83.84	52.47	39.31	35.04	91.65
Inventory	10.26	9.13	14.11	23.97	13.29	27.33
Prepaid Expenses	-	-	-	1.18	1.13	-
Other Current Assets	6.19	5.79	8.81	2.66	2.27	4.67
Total Current Assets	1,457	832.27	331.56	237.43	263.6	464.75
Property, Plant & Equipment	9.84	7.22	9.67	25.06	27.49	32.6
Long-Term Investments	156.87	167.95	10.91	49.32	3	-
Goodwill	101.54	101.54	105.25	103.37	105.67	105.67
Other Intangible Assets	209.24	225.44	266.65	299.61	352.64	386.8
Long-Term Accounts Receivable	194.23	196.88	185.02	62.29	-	-
Long-Term Deferred Tax Assets	37.12	8.35	0.07	0.21	8.53	35.73
Other Long-Term Assets	19.92	20.99	32.64	9.92	1.74	272.03
Total Assets	2,186	1,561	941.77	787.22	762.67	1,298

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	9.41	3.24	5.23	2.43	5.31	8.4
Accrued Expenses	29.49	29.08	25.53	10.09	13.3	12.4
Current Portion of Long-Term Debt	-	-	-	-	76.7	-
Current Portion of Leases	1.08	1.12	1.29	0.41	0.72	1.41
Current Income Taxes Payable	3.22	1.24	1.2	-	-	-
Current Unearned Revenue	-	-	-	1.22	0.36	0.65
Other Current Liabilities	3.54	2.78	3.86	2.63	2.43	18.8
Total Current Liabilities	46.74	37.45	37.11	16.78	98.81	41.67
Long-Term Debt	1,127	446.19	-	-	-	320.72
Long-Term Leases	3.78	4.23	5.86	5.77	10.34	2.31
Long-Term Unearned Revenue	-	-	18.18	15.14	0.04	-
Long-Term Deferred Tax Liabilities	21.65	36.02	32.52	31.62	30.62	30.86
Other Long-Term Liabilities	19.6	19.54	17.65	16.98	25.37	80.88
Total Liabilities	1,218	543.43	111.34	86.3	165.18	476.43

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.02	0.02	0.02	0.02	0.02	0.02
Additional Paid-In Capital	379.77	400.65	337.38	198.7	147.59	372.97
Retained Earnings	583.25	608.09	498.98	503.02	450.86	449.09
Comprehensive Income & Other	4.48	8.46	-5.94	-0.82	-0.98	-0.92
Shareholders' Equity	967.52	1,017	830.44	700.91	597.49	821.16
Total Liabilities & Equity	2,186	1,561	941.77	787.22	762.67	1,298

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1,131	451.54	7.15	6.18	87.75	324.44
Net Cash (Debt)	226.31	281.98	249.01	164.13	124.12	16.66
Net Cash Growth	-5.42%	13.24%	51.72%	32.23%	644.83%	-
Net Cash Per Share	10.56	13.89	13.61	9.24	7.36	0.97
Filing Date Shares Outstanding	19.94	19.94	19.26	17.71	17.08	16.85
Total Common Shares Outstanding	19.92	19.77	19.11	17.56	16.95	16.77
Working Capital	1,410	794.82	294.45	220.65	164.79	423.09
Book Value Per Share	48.57	51.44	43.46	39.92	35.25	48.97
Tangible Book Value	656.73	690.23	458.54	297.94	139.18	328.69
Tangible Book Value Per Share	32.97	34.91	24.00	16.97	8.21	19.60
Machinery	-	-	-	7.78	15.16	14.34
Construction In Progress	-	-	-	4.12	-	-
Leasehold Improvements	-	-	-	10.36	7.45	5.27

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 7, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 5, 2026

Data Sources Report a data error